ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Chip Petricoin on the Discovery of New Biomarkers

Emanuel F. Petricoin, III, PhD
Published: Monday, May 20, 2013

Emanuel F. “Chip” Petricoin III, PhD, Co-Director, Center for Applied Proteomics & Molecular Medicine, Professor of Life Sciences, George Mason University, discusses the discovery of new biomarkers in breast cancer.

There have been many large, publicly-funded biomarker discovery efforts, Petricoin says. The National Cancer Institute (NCI) has increase its effort to more methodically develop, discover, evaluate, and validate biomarkers. The process has been supported by the fact that many of these biomarkers have been approved by the FDA.

The NCI has also developed biomarkers that have translated well from the clinical to commercial setting in imaging, high-risk population screening, and recurrence monitoring.
 
Emanuel F. “Chip” Petricoin III, PhD, Co-Director, Center for Applied Proteomics & Molecular Medicine, Professor of Life Sciences, George Mason University, discusses the discovery of new biomarkers in breast cancer.

There have been many large, publicly-funded biomarker discovery efforts, Petricoin says. The National Cancer Institute (NCI) has increase its effort to more methodically develop, discover, evaluate, and validate biomarkers. The process has been supported by the fact that many of these biomarkers have been approved by the FDA.

The NCI has also developed biomarkers that have translated well from the clinical to commercial setting in imaging, high-risk population screening, and recurrence monitoring.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x